A Vancouver pharmaceutical company has been granted Health Canada approval for a wound care product that contains bovine collagen.
Merus Labs (CNSX:MR) has been granted approval to sell Collexa in Canada. Collexa is a product made by Ireland-based Innocoll. Merus has exclusive licensing rights to the product, a highly absorbent wound care material used to treat a variety of ulcers, abrasions and trauma wounds.
“With the approval of Collexa, Merus will provide Canadian patients with a stronger pipeline of products designed to greatly advance wound care treatment,” said Merus president and CEO Ahmad Doroudian.
Merus uses its expertise in the North American pharmaceutical markets and access to capital to license niche pharmaceutical products for sale in Canada and United States.
Twitter: nbennett_biv